Author(s): Bilotti E, Vesole DH, McBride L, Schmidt L, Gao Z,
Abstract Share this page
Abstract BACKGROUND: This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone. METHODS: Charts from 26 consecutive patients able to obtain commercial vorinostat were analyzed for response and safety data. RESULTS: The overall response rate was 31\%, and the clinical beneficial rate was 50\%. The median duration of response was 3 months, and the median overall survival was 28.5 months. The most common grade 3 and 4 toxicities were hematologic and metabolic, including neutropenia (44\%), thrombocytopenia (53\%), and transaminase elevations (aspartate aminotransferase 9\% and alanine aminotransferase 6\%). No thromboembolic events or febrile neutropenia were observed. CONCLUSION: These observations demonstrate that the addition of vorinostat to patients with lenalidomide- and dexamethasone-refractory multiple myeloma was associated with moderate response and was well-tolerated, warranting further assessment in a larger prospective study. Copyright © 2016 Elsevier Inc. All rights reserved.
This article was published in Clin Lymphoma Myeloma Leuk
and referenced in Advances in Pharmacoepidemiology and Drug Safety